ArsenalBio bolsters team via hirings of Sirichoke, Schroer; plus Moderna, Jubilant and Synlogic
Cell therapy company Arsenal Biosciences Inc. hired Tim Sirichoke as chief technical operations officer and John Schroer as CFO. Most recently Sirichoke was VP of individualized neo-antigen specific therapies manufacturing at Genentech Inc.; he also was VP of manufacturing at Kite Pharma and site quality head at Novartis AG (NYSE:NVS; SIX:NOVN). Schroer previously was CFO at Translate Bio Inc. (NASDAQ:TBIO) and managing director and healthcare sector head at Allianz Global Investors. ArsenalBio launched in 2019 with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome hurdles to cell therapy for solid tumors.
Moderna Inc. (NASDAQ:MRNA) hired Shannon Thyme Klinger as chief legal officer, effective June 1. Klinger previously served as chief legal officer at Novartis AG (NYSE:NVS; SIX:NOVN). She succeeds General Counsel Lori Henderson, who is retiring. ...